(a) Co-localization of FtsW-GFP and DAP-TMR in S. aureus cells during phase I binding. S. aureus RN4220 FtsW-GFP was grown to mid-exponential phase (OD600 = 0.5) followed by addition of Ca 2+ and a mixture of labelled and unlabelled DAP (1.6 µg ml -1 DAP; 0.16 µg ml -1 DAP-TMR). Excess DAP-TMR and non-labelled DAP was removed and cells imaged after 0.5 and 20 min by combining HILO microscopy with dual-color imaging using a dual-emission image splitter. Scale bar 1 µm. Representative images from 2 independent experiments are shown. (b) Sublethal concentrations of DAP lead to delocalization of the putative lipid II flippase FtsW. S. aureus cells expressing chromosomally encoded FtsW-GFP were treated with DAP (2 µg ml -1 ) in the presence of Ca 2+ and the cells subjected to fluorescence microscopy at the indicated time points. Phase, phase contrast. Scale bar 1 µm. Representative images from 3 independent experiments are shown. Supplementary Figure 5: Pre-treatment of S. aureus with VAN leads to increased lipid II levels and enhanced binding of DAP-FL. (a) TLC of lipids extracted from untreated cells (lane 2) or cells treated with VAN (5 µg ml -1 ) (lane 3) for 30 min. Purified lipid II was applied in lane 1. Representative images from 3 independent experiments are shown. (b) DAP-FL binding to S. aureus cells treated with VAN (5 µg ml -1 ) or oxacillin (5 µg ml -1 ) for 30 min followed by washing the cells twice and incubation with DAP (mixture of DAP-FL and native DAP) for 10 min in the presence of Ca 2+ . Lipid II is expected to be dispersed over the entire cell membrane, as a consequence of the strong accumulation. Scale bar 1 µm. Representative images from 3 independent experiments are shown. (c) Quantification of DAP-FL binding measured during the experiment described in (b). Fluorescence intensity of the untreated control cells was set as 1.Values are means from 4 (untreated, Vancomycin preincubated) or two (oxacillin treated) independent experiments. (d) Survival of S. aureus without treatment (blue line), after treatment with VAN (green line), treated with DAP (5 µg ml -1 ) (yellow line) or treated with DAP (5 µg ml -1 ) after pre-incubation with VAN (red line). Values are means from two independent experiments. Error bars in (c) and (d) represent the SD. Source data are provided as a Source Data file.
: DAP induces the LiaRS-mediated cell envelope stress response in B. subtilis in a dose-dependent manner. Induction of the LiaRS response in B. subtilis indicating interference with the lipid II biosynthesis cycle was examined by measuring PliaI-lux expression over time. Treatment with DAP elicited cell envelope stress at concentrations ranging from 0.5 to 4 µg ml -1 . Luciferase activity is presented as relative luminescence units (RLU). Representative graph of three independent experiments with comparable results. Source data are provided as a Source Data file.
Supplementary Figure 2: Septal binding of DAP entails killing of S. aureus cells. An S. aureus
culture was treated with DAP (7 µg ml -1 ) in the presence of Ca 2+ for 15 min followed by washing of the cells and incubation with sytox green. Cells were washed again and subjected to fluorescence microscopy. Arrows indicate cells with septal DAP localization that are intensively stained by sytox green. Phase, phase contrast. Scale bar 1 µm. Representative images from 3 independent experiments are shown.
Supplementary Figure 3: Schematic depiction of peptidoglycan biosynthesis in S. aureus.
The ultimate soluble peptidoglycan precursor UDP-MurNAc-pentapeptide is synthesized in the cytoplasm by the sequential action of MurA to MurF enzymes starting from UDP-GlcNAc provided by GlmS, GlmM and GlmU. The glycosyltransferase MraY transfers the soluble sugar-peptide moiety in the first membrane-associated step to the lipid carrier C55P producing lipid I. MurG subsequently links a GlcNAc moiety to the muramoyl portion of lipid I converting it to lipid II. Lipid II is further speciesspecifically modified by the addition of five glycine residues catalysed by the peptidyltransferases FemXAB and by amidation of the glutamate residue in position 2 of the stem peptide catalysed by the hetero bi-enzyme complex MurT/GatD. Finally, lipid II is translocated across the cytoplasmic membrane by members of the SEDS or MOP families, and the peptidoglycan monomer is incorporated into the growing peptidoglycan network by transglycosylation and transpeptidation promoted by penicillin binding proteins. GlcNAc, N-acetyl-glucosamine; MurNAc-pp, N-acetyl-muramic acid pentapeptide; C55P, undecaprenyl-phosphate; Gly5-bridge, pentaglycine interpeptide bridge; PG, phosphatidylglycerol; Gln, glutamine; TP, transpeptidase; TG, transglycosylase.
